Completed PHASE3 INTERVENTIONAL 2-arm NCT01014208

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma (ORCHARRD)

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant (ASCT) in Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Sponsor: GlaxoSmithKline

Conditions Lymphoma, Large-Cell, Diffuse

Interventions OFATUMUMAB + DHAP RITUXIMAB + DHAP

Updated 7 times since 2017 Last updated: Jul 9, 2015 Started: Mar 31, 2010 Primary completion: Feb 28, 2014 Completion: Nov 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Lymphoma, Large-Cell, Diffuse, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 7 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Aarhus, Denmark , Aichi, Japan , Akita, Japan , Amersfoort, Netherlands , Amsterdam, Netherlands , Athens, Greece , Bangkok, Thailand , Barcelona, Spain , Beijing, China and 129 more locations